T-Cell Engagers

T-cell engagers, or TCEs, are explained in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 as a class of bispecific-like drugs that connect tumor cells or disease-relevant cells to T cells. The episode treats them as a possible lower-cost, lower-intensity alternative to CAR-T, not as a full replacement.

The source’s main insight is spillover. CAR-T’s logic of redirecting immune cells creates interest in TCEs, especially in autoimmune diseases where clearing abnormal B-cell populations may be useful. The same immune activation that creates efficacy can also create toxicity if engagement is too broad or non-specific.

156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 adds the direct competition case. In multiple myeloma, the episode says Johnson & Johnson’s TCE and combination data can pressure Legend Biotech’s CAR-T expectations, showing that TCEs can be commercially disruptive even if they are not a universal CAR-T replacement.

Key Claims

• TCEs are cheaper and easier to administer than patient-specific CAR-T in the source’s account.
• The episode expects weaker effects than CAR-T, so the tradeoff is access and cost versus potency.
• Autoimmune disease interest comes from the possibility of clearing pathological B cells without full CAR-T manufacturing.
• Non-specific immune activation remains a safety risk, connecting the concept to Cytokine Release Syndrome.
• Episode 156 adds that TCEs can compete with CAR-T in specific disease-area portfolios when data, convenience, and partner strategy line up.

Connections

• CAR-T Cell Therapy, Ex Vivo CAR-T Manufacturing, and In Vivo CAR-T - CAR-T comparison routes.
• Cancer Immune Recognition Problem - immune-recognition logic TCEs borrow.
• Cytokine Release Syndrome - related immune-toxicity concern.
• Finite-Game Biotech Competition - reason a “weaker but cheaper” format can still matter commercially.
• Johnson & Johnson / 强生, Legend Biotech / 南京传奇, and Biotech BD Data Validation Phase - episode 156 competition and evidence context.